JP2022526420A5 - - Google Patents
Info
- Publication number
- JP2022526420A5 JP2022526420A5 JP2021559535A JP2021559535A JP2022526420A5 JP 2022526420 A5 JP2022526420 A5 JP 2022526420A5 JP 2021559535 A JP2021559535 A JP 2021559535A JP 2021559535 A JP2021559535 A JP 2021559535A JP 2022526420 A5 JP2022526420 A5 JP 2022526420A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- polypeptide sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962830598P | 2019-04-08 | 2019-04-08 | |
| US62/830,598 | 2019-04-08 | ||
| US201962861377P | 2019-06-14 | 2019-06-14 | |
| US62/861,377 | 2019-06-14 | ||
| US201962896790P | 2019-09-06 | 2019-09-06 | |
| US62/896,790 | 2019-09-06 | ||
| US201962928615P | 2019-10-31 | 2019-10-31 | |
| US62/928,615 | 2019-10-31 | ||
| PCT/US2020/025643 WO2020210067A1 (en) | 2019-04-08 | 2020-03-30 | Humanized anti-dll3 chimeric antigen receptors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022526420A JP2022526420A (ja) | 2022-05-24 |
| JP2022526420A5 true JP2022526420A5 (enExample) | 2022-06-15 |
Family
ID=72750831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559535A Pending JP2022526420A (ja) | 2019-04-08 | 2020-03-30 | ヒト化抗ｄｌｌ３キメラ抗原受容体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220184127A1 (enExample) |
| EP (1) | EP3952888A1 (enExample) |
| JP (1) | JP2022526420A (enExample) |
| KR (1) | KR20210150432A (enExample) |
| CN (1) | CN113795262A (enExample) |
| AU (1) | AU2020271012A1 (enExample) |
| BR (1) | BR112021016272A2 (enExample) |
| CA (1) | CA3132202A1 (enExample) |
| IL (1) | IL286984A (enExample) |
| MX (1) | MX2021012336A (enExample) |
| SG (1) | SG11202108759SA (enExample) |
| WO (1) | WO2020210067A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| JP7181438B2 (ja) * | 2019-08-06 | 2022-11-30 | アプリノイア セラピューティクス リミテッド | 病理学的タウ種に結合する抗体及びその使用 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| MX2023012614A (es) * | 2021-05-08 | 2023-11-03 | Shanghai Qilu Pharmaceutical Res And Development Centre Ltd | Molecula de union contra dll3 y uso de la misma. |
| AU2022339815A1 (en) * | 2021-09-02 | 2024-03-14 | Memorial Hospital For Cancer And Allied Diseases | Antigen recognizing receptors targeting dll3 and uses thereof |
| CN114790240B (zh) * | 2022-06-10 | 2023-06-06 | 郑州大学 | SARS-CoV-2中和性单克隆抗体及应用 |
| WO2024044779A2 (en) * | 2022-08-26 | 2024-02-29 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3) |
| CN116813784B (zh) * | 2023-05-17 | 2024-03-01 | 星奕昂(上海)生物科技有限公司 | 靶向dll3的抗体及其应用 |
| CN120731224A (zh) * | 2024-01-30 | 2025-09-30 | 石药集团巨石生物制药有限公司 | 抗dll3抗体及应用 |
| WO2025212519A1 (en) * | 2024-04-01 | 2025-10-09 | Moonlight Bio, Inc. | Dll3 binding proteins and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY149079A (en) * | 2006-10-02 | 2013-07-15 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor |
| AU2010303443A1 (en) * | 2009-10-09 | 2012-04-19 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-Her 3 antibodies |
| DK2530091T3 (en) * | 2010-01-29 | 2018-05-28 | Chugai Pharmaceutical Co Ltd | ANTI-DLL3 ANTIBODY |
| CA2799746C (en) * | 2010-05-17 | 2020-11-24 | Sai Reddy | Rapid isolation of monoclonal antibodies from animals |
| WO2012019061A2 (en) * | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
| JP2014529581A (ja) * | 2011-08-05 | 2014-11-13 | イフォム・フォンダツィオーネ・インスティトゥオ・フィルチ・ディ・オンコロジア・モレコラーレ | 構成的に活性なｕＰＡＲバリアントならびに阻害抗体の生成および単離へのそれの使用 |
| BR112014020826A8 (pt) * | 2012-02-24 | 2017-09-19 | Stem Centrx Inc | Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado |
| CN103173413A (zh) * | 2012-12-07 | 2013-06-26 | 天津三箭生物技术有限公司 | 小鼠抗人β-Catenin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
| GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| US9879087B2 (en) * | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| MA41613A (fr) * | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| WO2019067805A1 (en) * | 2017-09-27 | 2019-04-04 | University Of Southern California | NEW PLATFORMS FOR CO-STIMULATION, NEW CAR DESIGNS AND OTHER IMPROVEMENTS FOR ADOPTIVE CELL THERAPY |
| CA3097193A1 (en) * | 2018-05-08 | 2019-11-14 | Phanes Therapeutics, Inc. | Anti-dll3 antibodies and uses thereof |
-
2020
- 2020-03-30 CN CN202080027518.8A patent/CN113795262A/zh active Pending
- 2020-03-30 MX MX2021012336A patent/MX2021012336A/es unknown
- 2020-03-30 SG SG11202108759S patent/SG11202108759SA/en unknown
- 2020-03-30 EP EP20788157.4A patent/EP3952888A1/en not_active Withdrawn
- 2020-03-30 US US17/593,087 patent/US20220184127A1/en not_active Abandoned
- 2020-03-30 BR BR112021016272A patent/BR112021016272A2/pt not_active Application Discontinuation
- 2020-03-30 WO PCT/US2020/025643 patent/WO2020210067A1/en not_active Ceased
- 2020-03-30 KR KR1020217034403A patent/KR20210150432A/ko not_active Withdrawn
- 2020-03-30 AU AU2020271012A patent/AU2020271012A1/en not_active Abandoned
- 2020-03-30 CA CA3132202A patent/CA3132202A1/en active Pending
- 2020-03-30 JP JP2021559535A patent/JP2022526420A/ja active Pending
-
2021
- 2021-10-05 IL IL286984A patent/IL286984A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022526420A5 (enExample) | ||
| JP2022526841A5 (enExample) | ||
| JP2022527173A5 (enExample) | ||
| US11155615B2 (en) | Anti-ROR1 antibodies | |
| US7939072B2 (en) | Anti-EGFR antibodies with an improved anti-tumor activity and compositions and articles of manufacture comprising same | |
| JP2020501531A5 (enExample) | ||
| CN103533960B (zh) | c-KIT抗体及其用途 | |
| JP2021514664A5 (enExample) | ||
| IL276830B1 (en) | Anti-claudin 18.2 antibodies and their uses | |
| JP2020528750A5 (enExample) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2014531217A (ja) | ｃ−ＭｅｔのＳＥＭＡドメイン内のエピトープに特異的に結合する抗体 | |
| JP2021528047A5 (enExample) | ||
| JP2018503380A5 (enExample) | ||
| JP2024531409A5 (enExample) | ||
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| JP2015024994A (ja) | ＤＡＲＰｉｎを含む二重特異キメラ蛋白質 | |
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2022538475A5 (enExample) | ||
| US20250388682A1 (en) | Degradation of egfr using a bispecific binding agent | |
| US20250270323A1 (en) | Hhla2 binding agents with novel activity | |
| JP2023525991A5 (enExample) | ||
| JP2023534959A5 (enExample) | ||
| US9499622B2 (en) | Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins |